PTEN and prostate carcinoma: In particular the dual activity of 2-O-Bn-InsP5 can explain its effect in prostate cancer cells PC3, consistent with the recently reported key role of mTORC2 in the development of loss of Pten-driven prostate cancer (Guertin et al, 2009).